Nasal high flow improves ventilation during propofol sedation: A randomized cross-over study in healthy volunteers.
Autor: | Mishima G; Division of Clinical Physiology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Department of Dental Anesthesiology, Nagasaki University Hospital, Nagasaki, Japan., Sanuki T; Division of Clinical Physiology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Department of Dental Anesthesiology, Nagasaki University Hospital, Nagasaki, Japan., Revie J; Fisher & Paykel Healthcare Ltd, Auckland, New Zealand., Pinkham M; Fisher & Paykel Healthcare Ltd, Auckland, New Zealand., Watanabe T; Department of Dental Anesthesiology, Nagasaki University Hospital, Nagasaki, Japan., Kurata S; Department of Dental Anesthesiology, Nagasaki University Hospital, Nagasaki, Japan., Tatkov S; Fisher & Paykel Healthcare Ltd, Auckland, New Zealand., Ayuse T; Division of Clinical Physiology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Department of Dental Anesthesiology, Nagasaki University Hospital, Nagasaki, Japan. Electronic address: ayuse@nagasaki-u.ac.jp. |
---|---|
Jazyk: | angličtina |
Zdroj: | Respiratory physiology & neurobiology [Respir Physiol Neurobiol] 2020 Jun; Vol. 277, pp. 103429. Date of Electronic Publication: 2020 Mar 12. |
DOI: | 10.1016/j.resp.2020.103429 |
Abstrakt: | Objective: Hypoventilation and carbon dioxide (CO Methods: NHF of 30 L/min and 60 L/min with room air was applied during wakefulness and sedation in 10 male volunteers. Ventilation was monitored by respiratory inductance plethysmography, transcutaneous partial pressure of CO Results: During sedation, NHF of 30 L/min and 60 L/min reduced the TcCO Conclusion: During sedation with propofol, NHF without supplemental oxygen attenuated CO Competing Interests: Declaration of Competing Interest J. R., M. P., and S. T. are employees of Fisher & Paykel Healthcare Ltd, the manufacturers of the nasal high flow (NHF) devices used in the study. T. A. has received funding and support from Fisher & Paykel Healthcare Ltd. G. M., T. S., T. W., and S. K. have no declaration of interest. (Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |